Breaking Down Barriers for PAH Patient Risk Assessment Through EHR Systems
A Treatment for NYHA Class II-III Obstructive HCM Patients
Strategies for CV Risk Reduction in Complex T2D Patients
ASCVD Risk Reduction in Patients With T2D
Joshua Stolker, MD
PeerTargeting Lower LDL-C: The Role of Nonstatin Therapies in ASCVD